In one paragraphArticle in Physiological genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Gina ManyBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, United States.ORCID 0000-0003-4779-1690 Connor Scott Reynoso SpurrierDepartment of Orthopaedic Surgery, University of California San Diego, School of Medicine, La Jolla, California, United States.ORCID 0009-0008-6222-3839 Philip BorsellinoKirk Kerkorian School of Medicine, Nevada, Las Vegas, United States.
Joshua N AdkinsBiological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington, United States.ORCID 0000-0003-0399-0700 Christopher B NewgardDepartment of Medicine, Duke University, Durham, North Carolina, United States.ORCID 0000-0002-1293-691X Shlomit Radom-AizikPediatric Exercise and Genomics Research Center, University of California, Irvine, California, United States.ORCID 0009-0004-4023-7026 Dan M CooperPediatric Exercise and Genomics Research Center, University of California, Irvine, California, United States.ORCID 0000-0003-1736-775X Simon SchenkDepartment of Orthopaedic Surgery, University of California San Diego, School of Medicine, La Jolla, California, United States.
MoTrPAC study group
Funding
MoTrPAC Supplemental Funding for MillerU24AR071113 · NIAMS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Jon Peter Durda, Karyn A Esser · 2017 to 2026
$28.8MPAGES: Physical Activity Genomics, Epigenomics/transcriptomics SiteU24DK112331 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI STUART C. SEALFON, Martin John Walsh · 2017 to 2026
$18.5MStanford/Salk MoTrPAC Site for Genomes, Epigenomes and TranscriptomesU24DK112348 · NIDDK · STANFORD UNIVERSITY · PI Stephen Montgomery, MICHAEL P. SNYDER · 2017 to 2026
$18.4MMolecular Transducers of Physical Activity Consortium Adult Clinical CenterU01AR071130 · NIAMS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MUSI, NICOLAS, RASMUSSEN, BLAKE B · 2017 to 2024
$17.7MProMoTr: A Proteomics Center for MoTrPACU24DK112349 · NIDDK · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI Joshua N. Adkins · 2017 to 2026
$17.5MThe Exercise and Physical Activity Collaborative Team (ExPACT): a Proposed MoTrPAC Clinical CenterU01AR071133 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUFORD, THOMAS W, GOODPASTER, BRET H · 2017 to 2024
$16.7MA Biochemical Roadmap of Exercise Signaling - Pilot Project for MoTrPAC ConsortiumU24DK112340 · NIDDK · BROAD INSTITUTE, INC. · PI STEVEN A CARR, Clary B Clish · 2017 to 2026
$16.2MMoTrPAC DXA Quality ControlU01AR071128 · NIAMS · DUKE UNIVERSITY · PI HOUMARD, JOSEPH A, KRAUS, WILLIAM E · 2017 to 2025
$15.2MMolecular Transducers of Physical Activity Consortium - Colorado Clinical CenterU01AR071124 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI KOHRT, WENDY M · 2017 to 2024
$14.5MStanford MoTrPAC Bioinformatics CenterU24OD026629 · OD · STANFORD UNIVERSITY · PI ASHLEY, EUAN A, WHEELER, MATTHEW THOMAS · 2018 to 2023
$13.9MMichigan MoTrPAC Chemical Analysis Site (MiCAS)U24DK112342 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES F BURANT, CHARLES ROBERT EVANS · 2017 to 2026
$12.6MPennington MoTrPAC Adults - RenewalU01AR071160 · NIAMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI RAVUSSIN, ERIC · 2017 to 2024
$11.0MNIAMS NIH HHS R01 AR050429NIAMS NIH HHS U01 AR071124NIAMS NIH HHS U01 AR071128NIAMS NIH HHS U01 AR071130NIAMS NIH HHS U01 AR071133NIAMS NIH HHS U01 AR071150NIAMS NIH HHS U01 AR071158NIAMS NIH HHS U01 AR071160NIAMS NIH HHS U24 AR071113NIA NIH HHS U01 AG055133NIA NIH HHS U01 AG055135NIA NIH HHS U01 AG055137NIA NIH HHS U01 AG070928NIA NIH HHS U01 AG070959NIA NIH HHS U01 AG070960NIDDK NIH HHS U24 DK112326NIDDK NIH HHS U24 DK112331NIDDK NIH HHS U24 DK112340NIDDK NIH HHS U24 DK112341NIDDK NIH HHS U24 DK112342NIDDK NIH HHS U24 DK112348NIDDK NIH HHS U24 DK112349NIH HHS U24 OD026629OSC | Common Fund (NIH Common Fund) U01AG055133OSC | Common Fund (NIH Common Fund) U01AG055135OSC | Common Fund (NIH Common Fund) U01AG055137OSC | Common Fund (NIH Common Fund) U01AG070928OSC | Common Fund (NIH Common Fund) U01AG070959OSC | Common Fund (NIH Common Fund) U01AG070960OSC | Common Fund (NIH Common Fund) U24DK112326OSC | Common Fund (NIH Common Fund) U24DK112331OSC | Common Fund (NIH Common Fund) U24DK112340OSC | Common Fund (NIH Common Fund) U24DK112341OSC | Common Fund (NIH Common Fund) U24DK112342OSC | Common Fund (NIH Common Fund) U24DK112348OSC | Common Fund (NIH Common Fund) U24DK112349OSC | Common Fund (NIH Common Fund) U24OD026629
6 · The paper itselfAbstract
Incretin-based pharmacotherapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, have transformed the treatment of type 2 diabetes, with demonstrated benefits across multiple organ systems. Their success has driven the investigation of related gut-derived hormones, most prominently dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, but extend to other targets with similar metabolic functions. For this class of drugs, the extent to which organ health improvements are secondary to improved systemic glycemic control versus direct tissue signaling remains unclear, partly because receptor availability across tissues is poorly annotated. We leveraged data from the Molecular Transducers of Physical Activity Consortium to annotate incretin receptor expression across 17 tissues in Fischer 344 rats and the Genotype-Tissue Expression Portal for human-level receptor expression. Furthermore, given the role of exercise in the preservation of muscle mass during weight loss, we analyzed the effects of 1, 2, 4, or 8 wk of treadmill exercise training on incretin-related signaling at the epigenetic, transcript, and protein levels. Endurance training elicited sex- and tissue-specific changes in incretin receptor expression, including downregulation of
Indexed as
Endurance TrainingIncretinsPhysical Conditioning, AnimalSex CharacteristicsSignal TransductionAnimalsFemaleGlucagon-Like Peptide-1 ReceptorMaleRatsRats, Inbred F344Receptors, Gastrointestinal Hormonegastric inhibitory polypeptide receptorGlucagon-Like Peptide-1 ReceptorIncretinsReceptors, Gastrointestinal Hormoneexerciseincretinmultiomics
Identifiers
PMID42636194
PMCPMC13701792
What OpenQuestion holds
Textmetadata
Read underepoch 390